Becton, Dickinson and Company

Valuation Analysis

About the Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal

Becton, Dickinson and Company Stock at a Glance

Becton, Dickinson and Company (BDX) is currently trading at $146.24 with a market capitalization of $40.3B. The trailing P/E ratio stands at 25.52x, with a forward P/E of 10.92x. The 52-week range spans from $127.59 to $187.35; the current price is 21.9% below the yearly high. Year-over-year revenue growth stands at +5.2%. The net profit margin stands at 5.12%.

💰 Dividend

Becton, Dickinson and Company pays an annual dividend of $4.20 per share, representing a yield of 2.87%. The payout ratio stands at 72.95%.

📊 Analyst Rating

13 analysts rate Becton, Dickinson and Company (BDX) on consensus: Buy. The average price target is $180.69, implying +23.56% from the current price. Analyst price targets range from $150.00 to $225.00.

Becton, Dickinson and Company: The Investment Case in Detail

Becton, Dickinson and Company (BDX) operates in the Healthcare — specifically Medical Instruments & Supplies — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Wall Street consensus sits at Buy with an average price target implying roughly 23.56% upside from current levels — analyst sentiment is firmly constructive.

Valuation in Context

The PEG ratio at 1.11 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric. The EV/EBITDA multiple of 9.22x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

What to Watch Next

• The forward P/E of 10.92x is meaningfully below the trailing 25.52x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 23.56% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Risk Profile

The data points to relatively defensive market behavior.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Becton, Dickinson and Company?

Compare top-rated brokers — low fees, trusted providers, fully regulated.